Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors.
Jared M OdegardAhmed A OthmanKai-Wen LinAdele Y WangJonathan NazarenoOh Kyu YoonJohn LingLatesh LadP Rod DunbarDung ThaiEdmond AngNicholas WaldronSanjeev DevaPublished in: Journal for immunotherapy of cancer (2024)
NCT04049617.